BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Fish and Richardson
Fuji
US Department of Justice
Cerilliant
Colorcon
Julphar
US Army
Queensland Health

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,357,677

« Back to Dashboard

Which drugs does patent 8,357,677 protect, and when does it expire?

Patent 8,357,677 protects VASCEPA and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.
Summary for Patent: 8,357,677
Title:Methods of treating hypertriglyceridemia
Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Inventor(s): Manku; Mehar (England, GB), Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT)
Assignee: Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:13/608,775
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 8,357,677

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-001 Jul 26, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA ➤ Subscribe
Amarin Pharms VASCEPA icosapent ethyl CAPSULE;ORAL 202057-002 Feb 16, 2017 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,357,677

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,324,195 Methods of treating hypertriglyceridemia ➤ Subscribe
8,431,560 Methods of treating hypertriglyceridemia ➤ Subscribe
8,293,727 Methods of treating hypertriglyceridemia ➤ Subscribe
8,399,446 Methods of treating hypertriglyceridemia ➤ Subscribe
8,546,372 Methods of treating hypertriglyceridemia ➤ Subscribe
8,524,698 Methods of treating hypertriglyceridemia ➤ Subscribe
8,440,650 Methods of treating hypertriglyceridemia ➤ Subscribe
8,518,929 Methods of treating hypertriglyceridemia ➤ Subscribe
8,293,728 Methods of treating hypertriglyceridemia ➤ Subscribe
8,367,652 Methods of treating hypertriglyceridemia ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,357,677

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3037089 ➤ Subscribe
Spain 2426132 ➤ Subscribe
Hong Kong 1165698 ➤ Subscribe
Croatia P20130811 ➤ Subscribe
Russian Federation 2505292 ➤ Subscribe
Russian Federation 2013154780 ➤ Subscribe
Portugal 2395991 ➤ Subscribe
Russian Federation 2011137415 ➤ Subscribe
South Korea 20110110321 ➤ Subscribe
South Korea 101383006 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Cipla
UBS
Cerilliant
Fuji
Covington
Fish and Richardson
McKinsey
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot